Four Systems, Fourteen Days: What December 2025 Revealed About Surgical Robotics Competition

Four Systems, Fourteen Days: What December 2025 Revealed About Surgical Robotics Competition

Intuitive Surgical has run the soft tissue robotics category almost unopposed for two decades. A cluster of FDA actions packed into one month, a wave of venture capital, and a low cost challenger out of India suggest that is starting to change, though not as fast as the funding rounds imply.

Vectomat Insights Research Desk | Published: September 2026 | Category: Medical Devices, Surgical Robotics | 7-min read

For most of the past twenty years, buying a soft tissue surgical robot meant buying a da Vinci system. Intuitive Surgical's grip on general, urologic, and gynecologic robotic surgery has been the industry's defining structural fact, not a footnote in it. That grip loosened, at least on paper, in a two and a half week stretch in December 2025, when three rival systems cleared the FDA and a fourth filed for clearance. This piece looks at what actually happened in that window, what the capital markets are betting on around it, and where the harder technical and clinical questions still sit unanswered.

The Clearance Wave

On December 3, 2025, Medtronic's Hugo robotic assisted surgery system received its first FDA clearance, for urologic procedures, after years of trailing Intuitive in the U.S. market despite an earlier international launch. Eight days later, Intuitive itself expanded the smaller da Vinci SP platform with three new indications: inguinal hernia repair, gallbladder removal, and appendectomy, a sign that the incumbent is defending share at the low acuity end of the category rather than ceding it. On December 17, Cambridge based CMR Surgical picked up clearance for its upgraded Versius Plus system in cholecystectomy, positioning the device, by CMR's own account, as the second most used soft tissue robot worldwide outside the United States. In between, on December 8, India's SS Innovations filed a 510(k) application for its SSi Mantra platform covering multiple soft tissue procedures, the first step toward a U.S. entry the company expects to complete in the first half of 2026.

Source: Medtronic media release, Dec 3, 2025; MedTech Dive year end roundup; FierceBiotech; MassDevice.

None of this amounts to Intuitive losing the category. It amounts to regulators finally clearing a backlog of challengers that have been in development, in some cases, for the better part of a decade. Whether hospitals switch platforms is a separate and much slower question, one that turns on service contracts, surgeon retraining, and procurement cycles that clearances alone do not move.

Capital Is Ahead of the Clinical Evidence

Investors are not waiting for that switching question to resolve. Distalmotion raised $150 million on November 19, 2025, aimed at positioning its Dexter system for ambulatory surgery centers rather than hospital operating rooms, a distribution bet as much as a technology one. Cornerstone Robotics secured $200 million on November 13. Both rounds closed weeks before the clearance wave they were presumably underwriting, which is itself informative: the money moved on the expectation of regulatory clearance, not on comparative outcomes data against the incumbent. Intuitive's own published evidence base runs to thousands of peer reviewed studies accumulated since its first FDA clearance in 2000. None of the December 2025 entrants have anything close to that, and it will take years of real world use, not a single clearance letter, before hospitals can compare outcomes across platforms with any confidence. The venture money is betting that clearance plus a lower price will be enough to win share before that evidence gap closes, which is a bet on procurement behavior more than on medicine.

The Case Out of India

The most interesting entrant in the December wave is not chasing Intuitive on price alone, it is building its evidence base in a different regulatory environment first. SS Innovations, the Gurugram based maker of the SSi Mantra system, reported on May 27, 2025 that it had passed 4,000 robotic surgeries across more than 100 procedure types, including 215 cardiac cases, six of them performed by telesurgery within India, with no complications, injuries, or deaths disclosed in that count. The system is already approved in seven countries: India, Nepal, Ecuador, Guatemala, the Philippines, Indonesia, and Ukraine. A CE Mark application for Europe was expected to conclude in late 2025, ahead of the U.S. filing.

The company's own framing, in Chairman and CEO Dr. Sudhir Srivastava's words, is that the milestone reflects world class quality and growing acceptance by leading physicians. That framing deserves the same scrutiny any manufacturer's self reported safety record deserves: 4,000 cases is a meaningful start, not the scale at which rare complication rates become statistically visible, and the count comes from the manufacturer rather than an independent registry. What is genuinely notable is the strategy, not yet the safety data: a robotic platform built and proven first in a lower cost, high volume market, then exported outward, is close to the inverse of how Intuitive, Medtronic, and CMR built their businesses. If the U.S. filing clears in 2026 as the company expects, it will be the first real test of whether that sequencing works commercially outside the markets it was built for.

What Clearance Does Not Solve

The harder problems in the category are not regulatory. Telesurgery, the ability for a surgeon to operate on a patient in a different location, remains legally and technically unresolved almost everywhere it has been attempted: cross border licensing, liability in the event of a network failure mid procedure, and latency requirements that most public networks cannot reliably guarantee. SS Innovations' six telesurgery cases were performed within a single country's borders and regulatory system specifically because that removes most of those questions; a genuinely cross border telesurgery program has not yet been demonstrated at any meaningful scale by any manufacturer named here. Expansion into new procedure areas such as cardiac ablation carries a similar pattern: the mechanical capability tends to arrive well before the clinical trial infrastructure needed to prove it is actually better, or even equivalent, to existing manual techniques.

The honest read on December 2025 is that it was a regulatory unlock, not a competitive verdict. Four systems now have, or are seeking, an FDA pathway that did not exist cleanly a year earlier. Which of them actually takes hospital share from Intuitive, and on what evidence base, is a question 2026 and 2027 will answer, not one December alone could.

This article covers R&D, regulatory, and competitive developments only. Market sizing, segmentation, and forecasts for the Medical Robotics Market through 2035 are covered separately in the companion Vectomat Insights RDPR report.

Sources

1. Medtronic. "Medtronic announces FDA clearance of Hugo robotic assisted surgery system for urologic surgical procedures." Media release, December 3, 2025. news.medtronic.com.

2. MedTech Dive. "Robot developers make strides in 2025." Year end roundup. medtechdive.com.

3. FierceBiotech. "CMR Surgical grabs FDA clearance for upgraded Versius Plus robot." fiercebiotech.com.

4. MassDevice. "CMR Surgical wins FDA clearance for next gen Versius Plus robot in cholecystectomy." massdevice.com.

5. BioSpace. "SS Innovations Surpasses Milestone of 4,000 Robotic Surgeries Successfully Performed with the SSi Mantra Surgical Robotic System." Press release, May 27, 2025. biospace.com.

6. BW Healthcare World. "SS Innovations Submits FDA 510(k) For Made in India SSi Mantra Surgical Robot." bwhealthcareworld.com.

7. MedTech Dive. "How SS Innovations is expanding robotic surgery's reach." medtechdive.com.

Vectomat Insights is an independent healthcare and life sciences market intelligence practice. This article is editorial analysis prepared by the Vectomat Insights Research Desk from publicly available sources cited above and does not constitute investment, medical, or regulatory advice.